Risk factors for surgery-related muscle quantity and muscle quality loss and their impact on outcome

Laura van Wijk1*, Stijn van Duinhoven1, Mike S. L. Liem2, Donald E. Bouman3, Alain R. Viddeleer4 and Joost M. Klaase1,2

Abstract

Background: Surgery-related loss of muscle quantity negatively affects postoperative outcomes. However, changes of muscle quality have not been fully investigated. A perioperative intervention targeting identified risk factors could improve postoperative outcome. This study investigated risk factors for surgery-related loss of muscle quantity and quality and outcomes after liver resection for colorectal liver metastasis (CRLM).

Methods: Data of patients diagnosed with CRLM who underwent liver resection between 2006 and 2016 were analysed. Muscle quantity (psoas muscle index [PMI]), and muscle quality, (average muscle radiation attenuation [AMA] of the psoas), were measured using computed tomography. Changes in PMI and AMA of psoas after surgery were assessed.

Results: A total of 128 patients were analysed; 67 (52%) had surgery-related loss of muscle quantity and 83 (65%) muscle quality loss. Chronic obstructive pulmonary disease (COPD) (P = 0.045) and diabetes (P = 0.003) were risk factors for surgery-related loss of muscle quantity. A higher age (P = 0.002), open resection (P = 0.003) and longer operation time (P = 0.033) were associated with muscle quality loss. Overall survival was lower in patients with both muscle quantity and quality loss compared to other categories (P = 0.049). The rate of postoperative complications was significantly higher in the group with surgery-related loss of muscle quality.

Conclusions: Risk factors for surgery-related muscle loss were identified. Overall survival was lowest in patients with both muscle quantity and quality loss. Complication rate was higher in patients with surgery-related loss of muscle quality.

Keywords: Surgery-related muscle quantity loss, Surgery-related muscle quality loss, Psoas muscle index, Total psoas area, Liver resection, Colorectal liver metastasis

Introduction

Resection with curative intent is the treatment of choice for colorectal liver metastasis (CLRM) [1, 2]. Despite advances in surgical techniques and perioperative care, liver resection still causes substantial rates of postoperative morbidity and mortality [3–5]. Postoperative morbidity may result in prolonged hospital stays, increased healthcare costs, and potentially decreased long-term survival [6, 7]. In recent years, awareness has grown of using body composition variables as predictors for postoperative outcomes in surgery. Studies have demonstrated that low muscle mass referred to as sarcopenia negatively affects postoperative outcomes after resection.

*Correspondence:  l.van.wijk@umcg.nl
1 Department of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Hanzeplein 1, PO Box 30001, 9700 RB Groningen, the Netherlands
Full list of author information is available at the end of the article

© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
for CRLM [8, 9], and preoperative sarcopenia is associated with poor overall survival in patients with various solid tumours [10]. In addition, there is increasing evidence that preoperative low muscle radiation attenuation as a measure of muscle quality, also referred as myosteatosis, is also an important prognostic factor for impaired outcome in patients with cancer [11–13].

Although the impact of preoperative body composition variables has been well described in literature, less studies have investigated the process of surgery-related changes in muscle quantity and quality. Recent reports have suggested that loss of muscle quantity after surgery is associated with decreased quality of life and short-term outcomes [14–16]. In addition, the negative impact of this so-called surgery-related muscle loss (SML) on long-term survival after pancreatic surgery was recently demonstrated [17]. However, these studies only concern muscle quantity. There is minimal literature describing surgery-related changes in muscle quality [18].

Furthermore, through identifying risk factors for surgery-related loss of muscle quantity and quality, perioperative intervention might prevent or reduce SML and subsequently improve postoperative outcomes. Being aged above 65 years and diabetes were reported to be independent risk factors for clinically relevant loss of muscle quantity within 1 week of gastric cancer surgery [16]. Risk factors for surgery-related loss of muscle quality have not yet been described. The aim of this study is to identify risk factors for surgery-related loss of both muscle quantity and quality after liver resection for CRLM. In addition, we also investigate the impact of surgery-related loss of muscle quantity and quality on overall survival.

**Material and methods**

**Patients**

This retrospective study included patients who had undergone liver resection for CRLM at Medisch Spectrum Twente, Enschede, The Netherlands between October 2006 and September 2016. Patients were selected from a liver resection database containing prospectively collected patient, treatment, and outcome data. The inclusion criteria were (i) patients resected for CRLM with available and (ii) pre- and postoperative abdominal computed tomography (CT) scans (within 6 weeks before and 3 weeks after surgery). All patients were treated according to a multimodal Enhanced Recovery After Surgery (ERAS) pathway [19]. Postoperative CT scans were performed as part of a standard protocol and used as the baseline for oncological follow-up from 2011 onward. This study was approved by the Institutional Review Boards of the University Medical Center Groningen (Research registration number: 201800063) and Medisch Spectrum Twente.

**Data collection**

For each patient enrolled in the study, the following data were collected: patient characteristics, including age, sex, patient length, preoperative body mass index (BMI), preoperative carcinoembryonic antigen (CEA) blood level, and comorbidity, including the Charlson Comorbidity Index (CCI) and American Society of Anaesthesiologists (ASA) risk score; and surgical parameters, such as the type of operation (i.e., minor [≤3 segments] or major [≥3 segments]) resection, open or laparoscopic resection, and whether resection was combined with radiofrequency ablation [RFA]), operation time, and blood loss. Postoperative characteristics were also collected, which included all complications, complications clustered according to Clavien–Dindo scores (with major complications being defined as grade ≥3), and hospital length of stay. Follow-up survival data were collected from the patient charts.

**Image acquisition**

When multiple CT examinations were available within 6 weeks before and 3 weeks after surgery, the CT scans closest to the day of surgery were selected. All acquired scans had a slice thickness of 1–5 mm, using a 512 × 512 matrix. After the CT images were anonymised, they were exported from the Picture Archiving and Communication System (PACS) and stored in Digital Imaging and Communications in Medicine (DICOM) format for analysis.

**Image analysis**

As in previous studies investigating surgery-related muscle loss, the surgery-related change in muscles was evaluated using the Total Psoas Area (TPA) measured by abdominal CT at the level of the third lumbar vertebra [14, 15, 18]. The border of the psoas muscle was manually outlined by an experienced board (board certified radiologist, 12 years of experience, and experienced researcher) using in-house developed analysis software (SarcoMeas 0.54). The TPA was computed as the sum of all muscle voxels within the drawn cross-sectional areas of the right and left psoas muscles, where muscle is defined as a radiation attenuation from −29 to +150 Hounsfield units [20]. The TPA was normalised for the patient’s height by dividing the muscle area (in cm²) by the square of the patient’s height (in meters), resulting in the Psoas Muscle Index (PMI cm²/m²) [21]. The average muscle radiation attenuation (AMA) in Hounsfield units (HU) of the measured psoas voxels was also calculated.
Statistical analysis
Continuous data are presented as the mean ± standard deviation or as medians and ranges as appropriate. Categorical data were presented as quantity and proportion. Descriptive statistics were used to analyse the baseline characteristics of the study population. Characteristics and variables between patients with skeletal muscle loss and those without were compared using a two-sample independent t test for normally distributed numerical variables; a Mann–Whitney U test for numerical variables that were not normally distributed; and a Pearson $X^2$ test for binary variables. Any variable with $P<0.10$ in the univariate analysis was included in the multivariate regression analysis. A backward multivariate regression selection analysis was performed to identify independent risk factors for surgery-related muscle quantity and quality loss. The overall survival rates after surgical resection for CRLM were determined using the Kaplan–Meier method, and differences between groups were compared using the log-rank test. The data were analysed using SPSS version 25 (IBM, Armonk, NY, USA).

Results
Study population
A total of 340 patients underwent surgery for CRLM during the study period. No suitable CT scans were available within the selected time frames in 155 patients and patient’s height data were unavailable for 12 patients. In 45 patients, one or both CT scans were of insufficient quality to determine the TPA (for example, because of an incompletely visualised psoas muscle or excessive noise in non-diagnostic low-dose CTs). The remaining 128 patients were included in this study’s analysis.

Baseline and intra-operative characteristics
Table 1 lists the baseline and intra-operative characteristics of the study patients ($n=128$). Their mean age was 65.5 ± 8.7 years; 89 (69.5%) were men; and their mean BMI was 25.6 ± 3.1 (kg/m²). Most patients had a Charlson Comorbidity Index (CCI) of 0 (80.5%), 19 (14.8%) patients had a CCI of I, and only six patients had a CCI of II or III (4.7%). Preoperative CT scans were performed with a mean time before operation of 28.2 ± 9.6 days, whereas postsurgical CT scans were performed after a mean of 7.1 ± 3 days. Only 15 patients (11.7%) underwent laparoscopic liver resection, which were all minor resections. Most (81.3%) of operations were resections without radiofrequency ablation. Mean operation time for all patients was 134.2 ± 61.6 min.

Pre- and postoperative CT measures.
The mean preoperative PMI was 6.1 ± 1.7 cm²/m². The mean postoperative PMI was 6.0 ± 1.6 cm²/m². In 67 (52%) of the 128 patients we found surgery-related loss of muscle quantity (PMI) with a mean loss of 7.1% ± 5.7%. Patients with loss of muscle quantity had a significantly higher preoperative PMI (6.4 [SD 1.7]) compared to patients without loss of muscle quantity (5.7 [SD 1.5]) ($P=0.014$).

The mean preoperative AMA of psoas was 45.4 ± 7.5 HU. The mean postoperative AMA of psoas was 42.5 ± 9.5 HU. In 83 (65%) patients we found surgery-related loss of muscle quality (AMA of psoas) with a mean loss of 8.1 ± 5.6 HU. The preoperative AMA of the psoas was higher (46.9 HU [7.2]) in patients with surgery-related loss of muscle quality than in patients without surgery-related loss of muscle quality (42.7 HU [SD 7.1]) ($P=0.002$). Of the patients with loss of muscle quantity ($n=67$), most patients ($n=48$ [72%]) had also quantity loss. Of the patients with loss of muscle quality ($n=83$), most patients ($n=48$ [58%]) had also quality loss. However, no significant association was found ($P=0.091$). In this study, in the group with surgery-related loss of muscle quantity, a mean decrease in muscle volume of 7.1% was observed. In addition, in the group with quality loss, a decrease of 8.1 HU in radio density was observed.

Comparison of pre- and intraoperative characteristics of patients with and without loss of muscle quantity
In Table 1, comparisons of baseline and intra-operative characteristics between patients with and without loss of muscle quantity are presented. No significant differences in baseline factors between the two groups were found. Examining the intraoperative characteristics, a significant difference ($P=0.014$) was found between the percentage of combined procedures (resection and radio frequency ablation) in the group with loss of muscle quantity (26.9%) versus the group without loss of muscle quantity (9.8%). Other intraoperative characteristics, such as open versus laparoscopic, minor versus major surgery, blood loss, and operation time, were not significantly different between the two groups.

Comparison of pre- and intraoperative characteristics of patients with and without loss of muscle quality
Patients with surgery-related loss of muscle quantity were on average older (66.9 years [SD 7.8]) than patients without surgery-related loss of muscle quality (62.7 years [SD 9.6]) ($P=0.008$). No other significant differences in preoperative factors were found (Table 1). In patients with surgery-related loss of muscle quality, the rate of laparoscopic procedures was significantly lower (4.8%)
Table 1  Baseline and intra-operative characteristics in patients with and without surgery-related loss of muscle quantity or quality

| Factors                      | Total n = 128 (100%) |
|------------------------------|-----------------------|
|                              | Muscle quantity loss  |
|                              | n = 67 (52%)          |
|                              | No muscle quantity loss |
|                              | n = 61 (48%)          |
|                              | P-value                |
|                              | Muscle quality loss    |
|                              | n = 83 (65%)          |
|                              | No muscle quality loss |
|                              | n = 45 (35%)          |
|                              | P-value                |
| Age, mean (SD), years        | 65.5 (8.7)            |
| Sex, male                    | 89 (69.5%)            |
| BMI, mean (SD), kg/m2        | 25.6 (3.1)            |
| CEAa, median (IQR), μg/L     | 6.3 (2.8–22.3)        |
| ASA score                    | I                     |
|                              | 14 (10.9%)            |
|                              | II                    |
|                              | 107 (83.6%)           |
|                              | III                   |
|                              | 7 (5.5%)              |
| Comorbidities                | Diabetes              |
|                              | 7 (5.5%)              |
|                              | Chronic obstructive pulmonary disease |
|                              | 6 (4.7%)              |
| Charlson Comorbidity index   | 0                     |
|                              | 103 (80.5%)           |
|                              | I                     |
|                              | 19 (14.8%)            |
|                              | II                    |
|                              | 5 (3.9%)              |
|                              | III                   |
|                              | 1 (0.8%)              |
| CT scan                      | Time-frame pre-scan and OK, mean (SD), days |
|                              | 28.2 (9.6)            |
|                              | Time-frame OK and post-scan, mean (SD), days |
|                              | 7.1 (3.0)             |
| Operation type               | Laparoscopic/open     |
|                              | 15 (11.7%)/113 (88.3%) |
|                              | Minor/major           |
|                              | 74 (57.8%)/54 (42.2%) |
|                              | Resection/resection + RFA |
|                              | 104 (81.3%)/24 (18.8%) |
| Operation parameters         | Blood loss, median (IQR), mL |
|                              | 400 (200–750)         |
|                              | Operation time, mean (SD), min |
|                              | 134.2 (61.6)          |

**P**standard deviation, **IQR** interquartile range, **BMI** body mass index, **CEA** carcinoembryonic antigen, **ASA** American Society of Anaesthesiologists, **CT** computer tomography, **RFA** radiofrequency ablation

The values given are numbers of patients unless indicated otherwise. Bold variables were considered statistically significant (**P** < 0.05)

\[a\] 28 patients missing
**Table 2** Postoperative characteristics of patients with and without surgery-related loss of muscle quantity or quality

|                          | Total n = 128 (100%) | Muscle quantity loss n = 67 (52%) | No muscle quantity loss n = 61 (48%) | P-value | Muscle quality loss n = 83 (65%) | No muscle quality loss n = 45 (35%) | P-value |
|--------------------------|----------------------|-----------------------------------|-------------------------------------|---------|---------------------------------|-------------------------------------|---------|
| Complicated postoperative course | 52 (40.6%) | 25 (37.3%) | 27 (44.3%) | 0.424 | 39 (47%) | 13 (28.9%) | 0.047 |
| Cardiopulmonary          | 23 (18.0%) | 10 (14.9%) | 13 (21.3%) | 0.347 | 17 (20.5%) | 6 (13.3%) | 0.315 |
| Incisional SSI           | 8 (6.3%) | 5 (7.5%) | 3 (4.9%) | 0.552 | 6 (7.2%) | 2 (4.4%) | 0.534 |
| Intra-abdominal SSI      | 10 (7.8%) | 5 (7.5%) | 5 (8.2%) | 0.877 | 8 (9.6%) | 2 (4.4%) | 0.296 |
| Infectious, other        | 6 (4.7%) | 5 (7.5%) | 1 (1.6%) | 0.120 | 1 (1.2%) | 1 (2.2%) | 0.658 |
| Bacteraemia              | 2 (1.6%) | 2 (3.0%) | 0 (0.0%) | 0.174 | 6 (7.2%) | 0 (0.0%) | 0.065 |
| Bile leak (≥ ISGLS Grade B) | 5 (3.9%) | 1 (1.5%) | 4 (6.6%) | 0.140 | 3 (3.6%) | 2 (4.4%) | 0.817 |
| DGE (grade A, B or C)    | 5 (3.9%) | 2 (3.0%) | 3 (4.9%) | 0.573 | 4 (4.8%) | 1 (2.2%) | 0.469 |
| Thromboembolic event     | 3 (2.3%) | 1 (1.5%) | 2 (3.3%) | 0.505 | 2 (2.4%) | 1 (2.2%) | 0.947 |
| Bleeding                 | 1 (0.8%) | 1 (1.5%) | 0 (0.0%) | 0.338 | 1 (1.2%) | 0 (0.0%) | 0.460 |
| Single organ failure     | 3 (2.3%) | 1 (1.5%) | 2 (3.3%) | 0.505 | 2 (2.4%) | 1 (2.2%) | 0.947 |
| Other                    | 11 (8.6%) | 5 (7.5%) | 6 (9.8%) | 0.632 | 9 (10.8%) | 2 (4.4%) | 0.217 |
| Clavien–Dindo ≥ 3        | 18 (14.1%) | 9 (13.4%) | 9 (14.8%) | 0.830 | 13 (15.7%) | 5 (11.1%) | 0.479 |
| Length of hospital stay, mean (SD) | 9.7 (5.3) | 9.4 (4.5) | 10.0 (6.2) | 0.522 | 10.3 (4.3) | 8.6 (6.8) | 0.084 |

SSI surgical site infection, ISGLS International Study Group of Liver Surgery, DGE delayed gastric emptying, SD standard deviation, CT computed tomography

The values given are numbers of patients unless indicated otherwise. Bold variables were considered statistically significant (P < 0.05).

**Table 3** Linear regression analysis of pre- and intraoperative factors associated with surgery-related loss of muscle quantity

| Factors                        | Univariate analysis | Multivariate analysis |
|--------------------------------|---------------------|-----------------------|
|                                | B (95% CI)          | P-value               |
| Age (per 1 year increase)      | 0.036 (−0.161−0.234) | 0.716                 |
| Gender (male)                  | −3.240 (−6.928−0.448) | 0.085*                |
| BMI (per kg/m²)                | 0.132 (−1.063−1.326) | 0.828                 |
| CEAa (per μg/L)                | −0.007 (−0.029−0.016) | 0.553                 |
| ASA grade                      |                      |                       |
| I                              | −2.099 (−6.815−2.618) | 0.380                 |
| II                             | 5.417 (−2.078−12.911) | 0.155                 |
| Comorbidity                    |                      |                       |
| Diabetes                       | 10.778 (3.466−18.091) | **0.004**             |
| Chronic obstructive pulmonary disease | 7.307 (0.717−15.331) | 0.074*                |
| Surgery                        |                      |                       |
| Open resection (versus laparoscopic) | 1.314 (−4.022−6.649) | 0.627                 |
| Major (versus minor)           | −1.465 (−4.934−2.003) | 0.405                 |
| Resection + RFA (versus only resection) | 2.419 (−1.962−6.799) | 0.277                 |
| Blood loss (per ml)            | −0.001 (−0.003−0.001) | 0.383                 |
| Operation time (per min)       | −0.002 (−0.026−0.030) | 0.884                 |

BMI body mass index, CEA carcinoembryonic antigen, ASA American Society of Anesthesiologists, RFA radiofrequency ablation

Bold variables were considered statistically significant (P < 0.05). *Variables that were taken into the multivariable analysis (P < 0.010)

* 28 patients missing
compared to the other group (24.4%) \( (P=0.001) \). The duration of the operation was significant longer in the patients with surgery-related loss of muscle quality \( (P=0.035) \).

### Postoperative characteristics

Overall, 52 (40.6%) patients had a complicated postoperative course. Of all types of complication, cardiopulmonary complications occurred the most, \( (n=23 \ 18.0\%) \). There were no significant differences found between patients with or without surgery-related loss of muscle quantity for all types of postoperative complications and length of hospital stay. Patients with surgery-related loss of muscle quality had significantly more often a complicated postoperative course \( (P=0.047) \) compared to patients without loss of muscle quality, as presented in Table 2.

### Pre- and intraoperative risk factors for surgery-related loss of muscle quantity

Table 3 evaluates multiple factors that might be associated with surgery-related loss of muscle quantity. A univariate linear regression analysis suggests that male gender, the presence of chronic obstructive pulmonary disease (COPD) or diabetes are associated with higher percentages of surgery-related loss of muscle quantity \( (P<0.10) \). After a backward multivariate linear regression selection analysis, the presence of COPD or diabetes were identified as independent factors associated with higher percentage amounts of surgery-related loss of muscle quantity \( (P<0.05) \).

### Pre- and intraoperative risk factors for surgery-related loss of muscle quality

Table 4 evaluates multiple factors that might be associated with surgery-related loss of muscle quality. Univariate logistic regression analysis showed that a higher age, male gender, open resection and a longer operation time were associated with surgery-related loss of muscle quality \( (P<0.10) \). Multivariate logistic regression analysis demonstrated that a higher age, open resection and a longer operation time were significantly associated with surgery-related loss of muscle quality \( (P<0.05) \).

### Impact of surgery-related loss of muscle quantity and quality on survival

No significant differences in overall survival were found between patients with and without muscle quantity loss; however, a trend was seen (log-rank test, \( P=0.170 \)) (Fig. 1a). The overall survival in patients with muscle quality loss was significantly lower (log-rank test, \( P=0.012 \)) than that of patients without muscle quality loss (Fig. 1b). Patients without muscle quantity and quality muscle loss had significantly higher survival than

---

**Table 3** Logistic regression analysis of pre- and intraoperative factors associated with surgery-related loss of muscle quantity

| Factors                                      | Univariate analysis | Multivariate analysis |
|----------------------------------------------|---------------------|-----------------------|
|                                              | OR (95% CI)         | P-value               | OR (95% CI)         | P-value               |
| Age (per 1 year)                             | 1.059 (1.013–1.107) | 0.011*                | 1.082 (1.029–1.138) | 0.002                 |
| Gender (male)                                | 0.508 (0.234–1.103) | 0.087*                |                      |                       |
| BMI (per kg/m²)                              | 1.026 (0.911–1.154) | 0.674                 | 1.012 (0.996–1.029) | 0.130                 |
| CEAa (per μg/L)                              | 1.012 (0.996–1.029) | 0.130                 |                      |                       |
| ASA grade                                    |                     |                       |                      |                       |
| I                                            | 2.086 (0.795–5.473) | 2.086                 |                      |                       |
| II                                           | 1.378 (0.256–7.406) | 0.708                 |                      |                       |
| Comorbidity                                  | 1.378 (0.256–7.406) | 0.708                 |                      |                       |
| Diabetes                                     | 1.378 (0.256–7.406) | 0.708                 |                      |                       |
| Chronic obstructive pulmonary disease        | 1.089 (0.192–6.187) | 0.924                 |                      |                       |
| Surgery                                      | 1.800 (0.658–4.920) | 0.252                 | 1.001 (1.000–1.001)  | 0.127                 |
| Major (versus minor)                         | 1.149 (0.549–2.402) | 0.712                 |                      |                       |
| Open resection (versus laparoscopic)         | 6.390 (1.900–21.491)| 0.003*                | 6.798 (1.082–24.580) | 0.003                 |
| Resection+RFA (versus only resection)        | 1.800 (0.658–4.920) | 0.252                 |                      |                       |
| Blood loss (per ml)                          | 1.001 (1.000–1.001) | 0.127                 |                      |                       |
| Operation time (per min)                     | 1.007 (1.00–1.015)  | 0.041*                | 1.009 (1.001–1.017)  | 0.033                 |

*OR odds ratio, CI confidence interval, BMI body mass index, CEA carcinoembryonic antigen, ASA American Society of Anesthesiologists, RFA radiofrequency ablation

*Bold variables were considered statistically significant \( (P<0.05) \). *Variables that were taken into the multivariable analysis \( (P<0.010) \)

*28 patients missing
other categories, while patients with both muscle quantity and quality loss had significantly lower survival (log-rank test, \( P = 0.049 \)) (Fig. 1c).

**Discussion**

The results of the present study demonstrated that more than half of our patients had surgery-related loss of muscle quantity (52%) and/or loss of muscle quality (65%). COPD and diabetes were risk factors for surgery-related loss of muscle quantity. A higher age, open resection and longer operation time were significantly associated with surgery-related muscle quality loss. The rate of postoperative complications was significantly higher in the group with surgery-related loss of muscle quality. Patients with both muscle quantity and quality loss had the lowest survival.

In accordance with the findings of Huang et al. [16] diabetes was an independent risk factor for loss of muscle quantity. Diabetes can have negative effects on skeletal muscle function [22]. The impaired insulin function may cause the loss of body protein, particularly during the katabolic postoperative period [23, 24]. In the current study, patients with COPD also had a greater risk at loss of muscle quantity. Studies have suggested that chronic obstructive COPD causes respiratory and limb muscle dysfunction [25, 26]. However, the mechanisms for how COPD contributes to abdominal muscle atrophy or for surgery-related loss of muscle quantity remain
An underlying mechanism of why these patients were more prone to surgery-related muscle loss might be oxidative stress, which is inherent to pulmonary diseases such as COPD or asthma [29]. The oxidative stress could accelerate the process of muscle loss after surgery. However, due to the relatively small numbers of patients with COPD or diabetes, these results should be interpreted with caution and further research is needed to investigate the prognostic value of these two risk factors. Furthermore, a higher age was an independent predictor for surgery-related loss of muscle quality. Previous studies already found a correlation between a higher age and lower muscle quality [12] and quantity [16, 30, 31]. However, a correlation between a higher age and higher risk at surgery-related muscle loss has not been described before.

In this study, change in muscle quality was determined by the difference in AMA of the psoas on the pre- and postoperative CT-scan. All CTs were acquired after administration of intravenous contrast medium, according to the standard clinical protocol. This increases the radiodensity by 8 Hounsfield Units on average [32]. As all scans are acquired using the same contrast-enhanced protocol, the current results reflect the measurements in clinical setting and their direct usefulness in clinical practice. Low muscle radiation attenuation may be a reflection of increased water content (i.e., muscle edema) but is usually described as a marker for increased intramyocellular triglycerides (i.e., myosteatosis) [33, 34]. Though, in postoperative setting the decrease of muscle radiation attenuation should be interpreted with caution, since it might be influenced by perioperative fluid shifts. However, during the manual outlining of the muscle borders, the abdominal wall muscles in particular appeared to be affected by muscle edema and the presence of hematoma, especially in the operated right side, due to the subcostal incision, while the psoas muscles visually appeared unaffected by the direct surgical trauma and the surrounding fat did not show any edema. Therefore, in this study, it is assumed that the decrease in density is largely caused by myosteatosis and minimally caused by muscle edema.

Aoyama et al. [35] demonstrated that the greatest muscle loss occurs during the first postoperative week, and implied that this phenomenon was mainly because of increased catabolism caused by cytokine production under surgical stress. This mechanism is called the surgical stress response, which is the body’s response to prevent further injury through fluid conservation and substrate mobilisation. The surgical stress response comes with direct and indirect injury during surgery. Indirect surgical trauma occurs through events such as blood loss, alterations in blood pressure, and perfusion. Direct surgical injury is the result of incisions through different layers of the abdominal wall, the mobilisation of organs, and resection of organs or tissue [36]. The response starts with the release of cytokine and inflammatory mediators that control a complex process of metabolic, hormonal, and immunological processes, which subsequently results in the breakdown of muscle protein [37]. For example, surgical stress results in insulin resistance [38]. Myosteatosis has also been associated with insulin resistance, supporting the assumption that a postoperative decrease in muscle radiation attenuation of the psoas can be attributed to myosteatosis [34]. A higher degree of injury results in a higher peak and longer duration of cytokine release, as well as subsequent altered glucose metabolism, protein catabolism, and hormonal dysregulation [39]. Consequently, this leads to greater muscle loss. This explains why we found in our study that open surgery (versus laparoscopic) and a longer duration of the operation presented to be risk factors for surgery-related loss of muscle quality. This knowledge highlights the importance of minimally invasive surgery.

To our knowledge, there is only one previous study that investigated surgery-related changes in muscle quality analysed with abdominal CT-scan on outcome, rather than only muscle quantity [18]. Kobayashi et al. [18] investigated postoperative changes in skeletal muscle mass and muscle quality, and presented that postoperative loss of skeletal muscle quality was an independent risk factor for the recurrence of hepatocellular carcinoma in patients following a hepatectomy for hepatocellular carcinoma. Our study demonstrated that patients without out loss of muscle quantity and quality had significantly higher survival than other categories, while patients with both loss of muscle quantity and quality had significantly lower survival. Moreover, in our study the rate of postoperative complications was significantly higher in the group with surgery-related loss of muscle quality. These results emphasizing the need for further investigation into the aetiology and occurrence of surgery-related muscle loss and possible pathways for prevention [40]. Despite it has previous described that postoperative complications rates were higher in patients with surgery-related muscle quantity loss, [16] it is not yet clear whether the significant higher rates of postoperative complications were a cause or effect of surgery-related muscle quantity or quality loss. However, in the light of this: in contrast to other studies, postoperative CT scans in most patients were routinely performed as a standard protocol [9]. In this manner, we prevented the bias that CT scans probably create, because they are performed during a complicated course, which could theoretically influence the percentage of patients with SML.

Through identifying risk factors for SML, a perioperative intervention may prevent or reduce SML and
subsequently improve postoperative outcomes. Two important risk factors that contribute to muscle loss are malnutrition and inactivity. After surgery, adequate protein supplementation (1.5 g of protein per kg of body weight/day) can influence the surgical stress response and postoperative catabolism and subsequently treat declines in muscle mass, muscle strength, and functional capacity [41]. Also sufficient physical activity is critical for preventing muscle loss in patients [41, 42]. A combination of adequate protein intake and sufficient exercise has been shown to facilitate muscle gain [43–45]. Because of the retrospective nature of our study, data on postoperative protein and specific data on the degree of mobilisation of the included patients in our study were lacking. This lack of data are limitations of our research. Further research into postoperative protein intake and physical activity will be essential for setting up a proper and feasible protocol to prevent patients suffering muscle loss [37, 40]. Furthermore, a promising idea might be the application of neuromuscular electrical stimulation to muscles to maintain muscle thickness after surgery [46]. In conclusion, the current study demonstrated that surgery-related loss of muscle quantity or quality is present in more than half of the patients after liver resection for CRLM. Specific risk factors for SML could be identified. Overall survival was lowest in patients with both muscle quantity and quality loss, showing that surgery-related loss of muscle quality and quantity may be used in predicting prognosis. To reduce muscle loss, a perioperative programme focused on adequate protein intake combined with early mobilisation, especially for patients in risk groups, could be the first step.

Acknowledgements
Not applicable.

Authors’ contributions
Conception and design: LW, SD, AV, and JK. Provision of study materials or patients: ML, DB, AV, and JK. Collection and assembly of data: LW, SD, ML, DB, and AV. Data analysis and interpretation: all authors. All authors read and approved the final manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
Data are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the Institutional Review Boards of the University Medical Center Groningen (Research Registration Number: 201800063) and Medisch Spectrum Twente. All patients gave consent for inclusion in this study.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Author details
1 Department of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Hanzeplein 1, PO Box 30001, 9700 RB Groningen, the Netherlands. 2 Department of Surgery, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, the Netherlands. 3 Department of Radiology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ Enschede, the Netherlands. 4 Department of Radiology, University Medical Center Groningen, Hanzeplein 1, PO Box 30001, 9700 RB Groningen, the Netherlands.

Received: 11 September 2020 Accepted: 10 April 2021
Published online: 23 April 2021

References
1. van der Pool AE, Lalmahomed ZS, de Witt JH, Eggermont AM, Ijzermans JN, Verhoef C. Trends in treatment for synchronous colorectal liver metastases: differences in outcome before and after 2000. J Surg Oncol. 2010;102(3):413–8.
2. Lalmahomed ZS, Ayez N, van der Pool AE, Verheij J, Ijzermans JN, Verhoef C. Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome? World J Surg. 2011;35(3):656–61.
3. Dimick JB, Cowan JA, Knol JA, Upchurch GR. Hepatic resection in the United States: indications, outcomes, and hospital procedural volumes from a nationally representative database. Arch Surg. 2003;138(2):185–91.
4. Jarnagin WR, Conen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236(4):397–407.
5. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94(7):982–99.
6. Laurent C, Sa Cunha A, Couderc P, Puller E, Saric J. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg. 2003;90(9):2458–64.
7. Vigano L, Ferrero A, Lo Tesoriere R, Capussotti L. Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol. 2008;15(9):2458–64.
8. Peng PD, van Vledder MG, Tsai S, de Jong MC, Makary M, Ng J, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford). 2011;13(7):439–46.
9. van Vledder MG, Levolger S, Ijzermans JN, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg. 2012;99(4):S50–7.
10. Shachar SS, Williams GR, Misdrahi N, Misdrahi D, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford). 2011;13(7):439–46.
11. Alexo GFR, Shachar SS, Nyrop KA, Muss HB, Malpica L, Williams GR. Myosteatosis and prognosis in cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;145:102839.
12. van Dijk DP, Bakens MJ, Couderc P, Puller E, Saric J. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg. 2003;90(9):1131–6.
13. Weenink LBM, van der Hoorn A, van Leeuwen BL, de Bock GH, Bours MJ, et al. Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017;8(2):317–26.
14. Otsuji H, Yokoyama Y, Ebata T, Igami T, Sugawara G, Mizuno T, et al. Myosteatosis and prognosis in cancer: systematic review and meta-analysis. Br J Cancer. 2008;99(4):S50–7.
15. van Hagen PM, van Putten WLJ, van der Mark SD, et al. Improved survival in patients undergoing extended hepatic resection for colorectal metastases: is there a difference in surgical and oncological outcome? World J Surg. 2011;35(3):656–61.
16. van der Pool AE, Lalmahomed ZS, de Witt JH, Eggermont AM, Ijzermans JN, Verhoef C. Trends in treatment for synchronous colorectal liver metastases: differences in outcome before and after 2000. J Surg Oncol. 2010;102(3):413–8.
17. Lalmahomed ZS, Ayez N, van der Pool AE, Verheij J, Ijzermans JN, Verhoef C. Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome? World J Surg. 2011;35(3):656–61.
18. Dimick JB, Cowan JA, Knol JA, Upchurch GR. Hepatic resection in the United States: indications, outcomes, and hospital procedural volumes from a nationally representative database. Arch Surg. 2003;138(2):185–91.
19. Jarnagin WR, Conen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg. 2002;236(4):397–407.
20. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94(7):982–99.
21. Laurent C, Sa Cunha A, Couderc P, Puller E, Saric J. Influence of postoperative morbidity on long-term survival following liver resection for colorectal metastases. Br J Surg. 2003;90(9):1131–6.
22. Vigano L, Ferrero A, Lo Tesoriere R, Capussotti L. Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol. 2008;15(9):2458–64.
23. van Vledder MG, Levolger S, Ayez N, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg. 2012;99(4):S50–7.
24. Shachar SS, Williams GR, Misdrahi N, Misdrahi D, et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford). 2011;13(7):439–46.
25. van Vledder MG, Levolger S, Ijzermans JN, Verhoef C, Tran TC, Ijzermans JN. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg. 2003;90(9):1131–6.
16. Huang DD, Ji YB, Zhou DL, Li B, Wang SL, Chen XL, et al. Effect of surgery-induced acute muscle wasting on postoperative outcomes and quality of life. J Surg Res. 2017;218:58–66.

17. Choi MH, Yoon SB, Lee K, Song M, Lee IS, Lee MA, et al. Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. J Cachexia Sarcopenia Muscle. 2018;9(2):326–34.

18. Kobayashi A, Kaido T, Hamaguchi Y, Okumura S, Taura K, Hatano E, et al. Impact of postoperative changes in sarcopenic factors on outcomes after hepatectomy for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2016;23(1):57–64.

19. Chong CCN, Chung WY, Cheung YS, Fung AKY, Fong AKW, Lok HT, et al. Enhanced recovery after surgery for liver resection. Hong Kong Med J. 2019;25(2):94–101.

20. Aubrey J, Esfandiar N, Baracos VE, Buteau FA, Frenette J, Putman CT, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol. 2014;210(3):489–97.

21. Okugawa Y, Tsuchiya Y, Yamamoto A, Shigemori T, Kitamura A, Ichikawa T, et al. Close relationship between immunological/inflammatory markers and myopenia and myosteatosis in patients with colorectal cancer: a propensity score matching analysis. JPEN J Parenter Enteral Nutr. 2019;43(4):508–15.

22. Sun Z, Liu L, Liu N, Liu Y. Muscular response and adaptation to diabetes mellitus. Front Biosci. 2008;13:4765–94.

23. Schirrner T, Lattermann R. Perioperative catabolism. Can J Anaesth. 2015;62(2):182–93.

24. Park SW, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, de Rekeneire N, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care. 2009;32(11):1993–7.

25. Maltais F, Decramer M, Casaburi R, Barreiro E, Burelle Y, Debigare R, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care. 2009;32(11):1993–7.

26. Barreiro E, Gea J. Respiratory and limb muscle dysfunction in COPD. 2018;9(2):326–34.

27. Jaitovich A, Barreiro E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease: molecular basis and potential therapeutic targets. J Thorac Dis. 2018;10(Suppl. 12):S1415–24.

28. Jaitovich A, Barreiro E. Muscle atrophy in chronic obstructive pulmonary disease: molecular basis and potential therapeutic targets. J Thorac Dis. 2018;10(Suppl. 12):S1415–24.

29. Maltais F, Decramer M, Casaburi R, Barreiro E, Burelle Y, Debigare R, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care. 2009;32(11):1993–7.

30. Distefano G, Goodpaster BH. Effects of exercise and aging on skeletal muscle mass and function: measurement and physiology of muscle fibre atrophy and muscle fibre loss in humans. Ageing Res Rev. 2018;2018;194(4):284.

31. McMahon CJ, Wu JS, Eisenberg RL. Muscle edema. AJR Am J Roentgenol. 2010;194(4):284.

32. Goodpaster BH, Kelley DE, Leland Thaete F, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol. 2000;89(1):104–10.

33. Aoyama T, Kawabe T, Hirohito F, Hayashi T, Yamada T, Tsuchida K, et al. Body composition analysis within 1 month after gastrectomy for gastric cancer. Gastric Cancer. 2016;19(2):645–50.

34. Vanevski T, Webb MP, Menard B, Prabhakar A, Helmstetter J, Cornett EM, et al. Metabolic and the surgical stress response considerations to improve postoperative recovery. Curr Pain Headache Rep. 2019;23(5):33–4.

35. Carl F. Physiologic considerations of Enhanced Recovery After Surgery (ERAS) programs: implications of the stress response. Can J Anaesth. 2015;62(2):110–9.

36. Thorell A, Nygren L, Ljungqvist O. Insulin resistance: a marker of surgical stress. Curr Opin Clin Nutr Metab Care. 1999;2(1):69–78.

37. Scott MI, Miller TE. Pathophysiology of major surgery and the role of enhanced recovery pathways and the anesthesiologist to improve outcomes. Anesthesiol Clin. 2015;33(1):79–91.

38. Judah EK, Laura VW, Carlijn IB, Alain RV, Geertruida H, Cees P, et al. Impact and risk factors for clinically relevant surgery-related muscle loss in patients after major abdominal cancer surgery: study protocol for a prospective observational cohort study (MUSCLE POWER). Int J Clin Trials. 2019;6(3):138.

39. Deutz NE, Bauer JM, Barazzoni R, Bolo G, Borrie Y, Bosy-Westphal A, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr. 2014;33(6):929–36.

40. Snijders T, Trommelen J, Kouw IW, Holwerda AM, Verdijk LB, van Loon LJ. The impact of pre-sleep protein ingestion on the skeletal muscle adaptive response to exercise in humans: an update. Front Nutr. 2019;6:17.

41. Beaudart C, Dawson A, Shaw SC, Harvey NC, Kanis JA, Binkley N, et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int. 2017;28(6):1817–33.

42. Tieland M, Dirks ML, van der Zwaluw N, Verdijk LB, van de Rest O, de Groot LC, et al. Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc. 2012;13(8):713–9.

43. Kouw IW, Holwerda AM, Trommelen J, Kramer IF, Bastaande J, Halsen SL, et al. Protein ingestion before and after sleep increases overnight muscle protein synthesis rates in healthy older men: a randomized controlled trial. J Nutr. 2017;147(12):2252–61.

44. Hanada M, Soyama A, Hidaka M, Nagura H, Oikawa M, Tsuji A, et al. Effects on muscle and fat mass and body composition measured by dual-energy X-ray absorptiometry after low-dose and low-volume surgery for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2016;23(1):57–64.

45. Kouw IW, Holwerda AM, Trommelen J, Kramer IF, Bastaande J, Halsen SL, et al. Protein ingestion before and after sleep increases overnight muscle protein synthesis rates in healthy older men: a randomized controlled trial. J Nutr. 2017;147(12):2252–61.

46. Hanada M, Soyama A, Hidaka M, Nagura H, Oikawa M, Tsuji A, et al. Effects on muscle and fat mass and body composition measured by dual-energy X-ray absorptiometry after low-dose and low-volume surgery for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2016;23(1):57–64.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.